Axo Longevity Raises $5M Seed for Membership-Based Preventive Health Platform

Axo Longevity Raises $5M Seed Round

Axo Longevity, a membership-based preventive health platform founded in 2025 and headquartered in London and Madrid, has raised a $5 million seed round. The round includes participation from Everywhere Ventures, MS&AD Ventures, LifeX Ventures, Cistern Capital, Izou Partners, UNQ, 51 Ventures, NIAN Sports & Entertainment, Jorge Planas, and Daniel Kulle.

What Axo Longevity Does

Axo Longevity operates a membership model for preventive health. Members receive:

• Comprehensive blood panels analysing more than 100 biomarkers
• An Axo Health Score that includes biological age
• Personalised health plans based on member data

Testing is delivered through a partner network of more than 1,400 laboratory locations, giving members broad physical access to diagnostics rather than relying on a single-clinic model.

The company is also developing an AI health copilot and wearable device integrations, extending the membership experience beyond periodic testing toward continuous engagement with member health data.

Geographic Footprint

Axo Longevity operates in six markets:

• United Kingdom
• Ireland
• Spain
• Germany
• Netherlands
• Peru

With headquarters in London and Madrid, the company is building a European-centred footprint with an additional presence in Latin America. The multi-country operating model is supported by the partner laboratory network, which allows the company to serve members across markets without owning the full testing infrastructure.

Why the Round Matters

The preventive health and longevity category has attracted growing consumer and investor interest, and Axo Longevity's seed round provides capital to scale a membership platform that combines diagnostics, scoring, and personalised planning. The investor list spans venture funds and individual investors, including participation from MS&AD Ventures, the corporate venture arm associated with a major insurance group — a relevant strategic connection for a preventive health business.

For the company, the funding supports expansion of a model built on three layers: broad diagnostic access through partner labs, a proprietary scoring layer in the Axo Health Score with biological age, and a personalisation layer delivered through health plans. The announced development of an AI health copilot and wearable integrations points to a fourth layer aimed at ongoing member engagement between tests.

Round Details

• Company: Axo Longevity
• Founded: 2025
• Headquarters: London and Madrid
• Round type: Seed
• Amount: $5,000,000
• Participating investors: Everywhere Ventures, MS&AD Ventures, LifeX Ventures, Cistern Capital, Izou Partners, UNQ, 51 Ventures, NIAN Sports & Entertainment, Jorge Planas, Daniel Kulle
• Funding date: September 15, 2026

What to Watch

Key questions for Axo Longevity following the raise include how quickly it expands within its existing six markets, whether the AI health copilot and wearable integrations move from development into the member experience, and how the membership model performs across markets with differing healthcare systems and consumer expectations. The breadth of the investor group — spanning venture funds, strategic investors, and individuals — suggests a syndicate assembled to support both consumer growth and health-sector partnerships.